IBO
Impact BioMedical Inc.
Price Chart
Latest Quote
$0.50
-0.04 (-7.47%)
Current Price
| Previous Close | $0.54 |
| Open | $0.54 |
| Day High | $0.55 |
| Day Low | $0.49 |
| Volume | 152,587 |
Stock Information
| Shares Outstanding | 107.82M |
| Cash Equivalents | $20K |
| Revenue | $39K |
| Net Income | $-12.86M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $53.66M |
| EPS (TTM) | $-0.29 |
| Exchange | ASE |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $56.89M |
| Sales | $39K |
| Income | $-12.86M |
| Book/sh | $0.11 |
| Cash/sh | $0.00 |
| Employees | 2 |
Financial Ratios
| Quick Ratio | 0.01 |
| Current Ratio | 0.22 |
Returns & Margins
| ROA | -18.68% |
| ROE | -119.66% |
| Operating Margin | -32700.00% |
Ownership
| Insider Ownership | 89.02% |
| Institutional Ownership | 3.45% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/S | 1375.96 |
| P/B | 4.70 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.54 |
| SMA50 | $0.59 |
| SMA200 | $0.55 |
| RSI | 42.95 |
| ATR | 0.0481 |
| Shares Float | 11.49M |
| Short Float | 6.39% |
| Short Ratio | 14.89 |
| Rel Volume | 1.86 |
Performance History
| Week | -8.79% |
| Month | -8.46% |
| Quarter | -19.68% |
| 6 Months | -23.27% |
| YTD | -4.05% |
| Year | -69.07% |
| 10 Years | -81.42% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $0.50 | 152,600 |
| 2026-06-23 | $0.54 | 67,200 |
| 2026-06-22 | $0.53 | 46,400 |
| 2026-06-18 | $0.50 | 105,500 |
| 2026-06-17 | $0.58 | 44,400 |
| 2026-06-16 | $0.55 | 21,800 |
| 2026-06-15 | $0.55 | 69,200 |
| 2026-06-12 | $0.58 | 54,300 |
| 2026-06-11 | $0.56 | 60,100 |
| 2026-06-10 | $0.57 | 120,700 |
| 2026-06-09 | $0.58 | 288,600 |
| 2026-06-08 | $0.56 | 149,300 |
| 2026-06-05 | $0.57 | 76,700 |
| 2026-06-04 | $0.56 | 63,900 |
| 2026-06-03 | $0.54 | 53,300 |
| 2026-06-02 | $0.52 | 64,000 |
| 2026-06-01 | $0.55 | 61,600 |
| 2026-05-29 | $0.52 | 27,600 |
| 2026-05-28 | $0.51 | 34,100 |
| 2026-05-27 | $0.49 | 80,000 |
| 2026-05-26 | $0.51 | 33,600 |
About Impact BioMedical Inc.
Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. It also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, the company develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use as health supplements and medications. Further, it is developing 3F (functional fragrance formulation), a formulation of botanical ingredients. Impact BioMedical Inc. was incorporated in 2018 and is based in Houston, Texas. Impact BioMedical Inc. operates as a subsidiary of DSS BioHealth Security, Inc
đ° Latest News
No news articles available at the moment. Check back later for updates on IBO.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $424,000 | $0 | - | - |
| Cost Of Revenue | $424,000 | $0 | - | - |
| Total Revenue | $32,000 | $0 | $0 | $50,000 |
| Operating Revenue | $32,000 | $0 | $0 | $50,000 |
| Expenses | ||||
| Interest Expense | $793,000 | $1,065,000 | $444,000 | $462,000 |
| Total Expenses | $4,302,000 | $3,397,000 | $4,028,000 | $3,454,000 |
| Rent Expense Supplemental | $74,000 | $32,000 | $0 | - |
| Other Income Expense | $-9,400,000 | $-20,288,000 | $52,000 | $-4,034,000 |
| Other Non Operating Income Expenses | $-9,388,000 | $5,068,000 | $52,000 | $66,000 |
| Net Non Operating Interest Income Expense | $-780,000 | $-1,052,000 | $-431,000 | $-438,000 |
| Interest Expense Non Operating | $793,000 | $1,065,000 | $444,000 | $462,000 |
| Operating Expense | $3,878,000 | $3,397,000 | $4,028,000 | $3,454,000 |
| Other Operating Expenses | $417,000 | $171,000 | $119,000 | $68,000 |
| Selling And Marketing Expense | $24,000 | $633,000 | $65,000 | $325,000 |
| General And Administrative Expense | $1,952,000 | $1,196,000 | $1,039,000 | $1,047,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-11,838,000 | $-24,708,000 | $-4,336,000 | $-7,051,000 |
| Net Interest Income | $-780,000 | $-1,052,000 | $-431,000 | $-438,000 |
| Interest Income | $13,000 | $13,000 | $13,000 | $24,000 |
| Normalized Income | $-11,828,148 | $-4,676,760 | $-4,336,000 | $-3,274,900 |
| Net Income From Continuing And Discontinued Operation | $-11,838,000 | $-24,708,000 | $-4,336,000 | $-7,051,000 |
| Total Operating Income As Reported | $-4,282,000 | $-28,753,000 | $-4,028,000 | $-3,404,000 |
| Net Income Common Stockholders | $-11,838,000 | $-24,708,000 | $-4,336,000 | $-7,051,000 |
| Net Income | $-11,838,000 | $-24,708,000 | $-4,336,000 | $-7,051,000 |
| Net Income Including Noncontrolling Interests | $-11,870,000 | $-24,770,000 | $-4,407,000 | $-7,255,000 |
| Net Income Continuous Operations | $-11,870,000 | $-24,770,000 | $-4,407,000 | $-7,255,000 |
| Pretax Income | $-14,450,000 | $-24,737,000 | $-4,407,000 | $-7,876,000 |
| Special Income Charges | $-12,000 | $-25,356,000 | $0 | $-4,100,000 |
| Interest Income Non Operating | $13,000 | $13,000 | $13,000 | $24,000 |
| Operating Income | $-4,270,000 | $-3,397,000 | $-4,028,000 | $-3,404,000 |
| Depreciation Amortization Depletion Income Statement | $1,145,000 | $1,119,000 | $1,120,000 | $1,113,000 |
| Depreciation And Amortization In Income Statement | $1,145,000 | $1,119,000 | $1,120,000 | $1,113,000 |
| Gross Profit | $-392,000 | $0 | - | - |
| Amortization Of Intangibles Income Statement | - | - | $1,120,000 | $1,113,000 |
| Per Share | ||||
| Diluted EPS | $-0.38 | $-2.30 | $-0.07 | $-0.61 |
| Basic EPS | $-0.38 | $-2.30 | $-0.07 | $-0.61 |
| Other | ||||
| Tax Effect Of Unusual Items | $-2,148 | $-5,324,760 | $0 | $-323,900 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-12,500,000 | $2,803,000 | $-2,843,000 | $-2,201,000 |
| Total Unusual Items | $-12,000 | $-25,356,000 | $0 | $-4,100,000 |
| Total Unusual Items Excluding Goodwill | $-12,000 | $-25,356,000 | $0 | $-4,100,000 |
| Reconciled Depreciation | $1,145,000 | $1,119,000 | $1,120,000 | $1,113,000 |
| EBITDA (Bullshit earnings) | $-12,512,000 | $-22,553,000 | $-2,843,000 | $-6,301,000 |
| EBIT | $-13,657,000 | $-23,672,000 | $-3,963,000 | $-7,414,000 |
| Diluted Average Shares | $31,550,457 | $10,757,147 | $60,248,078 | $11,497,703 |
| Basic Average Shares | $31,550,457 | $10,757,147 | $60,248,078 | $11,497,703 |
| Diluted NI Availto Com Stockholders | $-11,838,000 | $-24,708,000 | $-4,336,000 | $-7,051,000 |
| Minority Interests | $32,000 | $62,000 | $71,000 | $204,000 |
| Tax Provision | $-2,580,000 | $33,000 | $0 | $-621,000 |
| Gain On Sale Of Ppe | $-12,000 | - | - | - |
| Impairment Of Capital Assets | $0 | $25,356,000 | $0 | - |
| Research And Development | $340,000 | $278,000 | $1,685,000 | $1,226,000 |
| Selling General And Administration | $1,976,000 | $1,829,000 | $1,104,000 | $1,047,000 |
| Other Gand A | $1,878,000 | $1,164,000 | $1,039,000 | $1,047,000 |
| Rent And Landing Fees | $74,000 | $32,000 | $0 | - |
| Write Off | - | - | $0 | $4,100,000 |
| Amortization | - | - | $1,120,000 | $1,113,000 |
Fetched: 2026-06-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-4,385,000 | $-13,549,000 | $-18,792,000 | $-15,569,000 |
| Total Assets | $17,405,000 | $20,290,000 | $44,633,000 | $46,497,000 |
| Total Non Current Assets | $16,994,000 | $17,842,000 | $44,301,000 | $46,375,000 |
| Non Current Note Receivables | $0 | $17,000 | $0 | $190,000 |
| Goodwill And Other Intangible Assets | $16,994,000 | $17,808,000 | $44,014,000 | $45,127,000 |
| Other Intangible Assets | $16,994,000 | $17,808,000 | $18,921,000 | $20,034,000 |
| Current Assets | $411,000 | $2,448,000 | $332,000 | $122,000 |
| Prepaid Assets | $142,000 | $265,000 | $0 | $61,000 |
| Inventory | $63,000 | $0 | - | - |
| Receivables | $203,000 | $184,000 | $331,000 | $16,000 |
| Notes Receivable | $198,000 | $184,000 | $203,000 | $16,000 |
| Accounts Receivable | $5,000 | $0 | - | - |
| Cash Cash Equivalents And Short Term Investments | $3,000 | $1,999,000 | $1,000 | $2,000 |
| Cash And Cash Equivalents | $3,000 | $1,999,000 | $1,000 | $2,000 |
| Cash Financial | $3,000 | $1,999,000 | $1,000 | - |
| Other Receivables | - | - | $128,000 | - |
| Other Non Current Assets | - | - | - | $782,000 |
| Other Current Assets | - | - | - | $104,000 |
| Debt | ||||
| Net Debt | - | $6,879,000 | $12,073,000 | $9,989,000 |
| Total Debt | - | $8,878,000 | $12,074,000 | $9,991,000 |
| Current Debt And Capital Lease Obligation | - | $8,878,000 | $12,074,000 | $9,991,000 |
| Current Debt | - | $8,878,000 | $12,074,000 | $9,991,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $1,850,000 | $13,053,000 | $16,371,000 | $13,828,000 |
| Total Non Current Liabilities Net Minority Interest | $688,000 | $3,268,000 | $3,235,000 | $3,235,000 |
| Non Current Deferred Liabilities | $688,000 | $3,268,000 | $3,235,000 | $3,235,000 |
| Non Current Deferred Taxes Liabilities | $688,000 | $3,268,000 | $3,235,000 | $3,235,000 |
| Current Liabilities | $1,162,000 | $9,785,000 | $13,136,000 | $10,593,000 |
| Current Notes Payable | $0 | $8,878,000 | $12,074,000 | $9,991,000 |
| Payables And Accrued Expenses | $1,162,000 | $907,000 | $1,062,000 | $602,000 |
| Payables | $968,000 | $713,000 | $832,000 | $539,000 |
| Accounts Payable | $347,000 | $314,000 | $832,000 | $539,000 |
| Equity | ||||
| Common Stock Equity | $12,609,000 | $4,199,000 | $25,162,000 | $29,558,000 |
| Total Equity Gross Minority Interest | $15,555,000 | $7,237,000 | $28,262,000 | $32,669,000 |
| Stockholders Equity | $12,609,000 | $4,259,000 | $25,222,000 | $29,558,000 |
| Retained Earnings | $-49,507,000 | $-37,669,000 | $-12,961,000 | $-8,625,000 |
| Preferred Stock Equity | - | $60,000 | $60,000 | - |
| Long Term Equity Investment | - | - | - | $782,000 |
| Investments In Other Ventures Under Equity Method | - | - | - | $782,000 |
| Other | ||||
| Ordinary Shares Number | $104,621,231 | $11,503,955 | $11,497,703 | $11,497,703 |
| Share Issued | $104,621,231 | $11,503,955 | $11,497,703 | $11,497,703 |
| Tangible Book Value | $-4,385,000 | $-13,609,000 | $-18,852,000 | $-15,569,000 |
| Invested Capital | $12,609,000 | $13,077,000 | $37,236,000 | $39,549,000 |
| Working Capital | $-751,000 | $-7,337,000 | $-12,804,000 | $-10,471,000 |
| Total Capitalization | $12,609,000 | $4,259,000 | $25,222,000 | $29,558,000 |
| Minority Interest | $2,946,000 | $2,978,000 | $3,040,000 | $3,111,000 |
| Additional Paid In Capital | $62,011,000 | $41,857,000 | $38,113,000 | $38,113,000 |
| Capital Stock | $105,000 | $71,000 | $70,000 | $70,000 |
| Common Stock | $105,000 | $11,000 | $10,000 | $70,000 |
| Preferred Stock | $0 | $60,000 | $60,000 | $0 |
| Current Accrued Expenses | $194,000 | $194,000 | $230,000 | $63,000 |
| Dueto Related Parties Current | $621,000 | $399,000 | - | - |
| Net PPE | $0 | $17,000 | $287,000 | $276,000 |
| Accumulated Depreciation | $0 | $-13,000 | $-6,000 | $0 |
| Gross PPE | $0 | $30,000 | $293,000 | $276,000 |
| Machinery Furniture Equipment | $0 | $30,000 | $30,000 | $25,000 |
| Finished Goods | $63,000 | $0 | - | - |
| Goodwill | - | $0 | $25,093,000 | $25,093,000 |
| Construction In Progress | - | $0 | $263,000 | $251,000 |
| Investments And Advances | - | - | $0 | $782,000 |
| Other Investments | - | - | $0 | $782,000 |
Fetched: 2026-06-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-1,890,000 | $-2,854,000 | $-2,869,000 | $-2,518,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-1,890,000 | $-2,854,000 | $-2,851,000 | $-2,242,000 |
| Cash Flow From Continuing Operating Activities | $-1,890,000 | $-2,854,000 | $-2,851,000 | $-2,242,000 |
| Operating Gains Losses | $12,000 | - | - | - |
| Investing Activities | ||||
| Investing Cash Flow | $3,000 | $2,000 | $-15,000 | $-349,000 |
| Cash Flow From Continuing Investing Activities | $3,000 | $2,000 | $-15,000 | $-349,000 |
| Net Other Investing Changes | $3,000 | $2,000 | $3,000 | $-8,000 |
| Capital Expenditure | - | - | $-18,000 | $-276,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $3,726,000 | $0 | - |
| Financing Cash Flow | $-109,000 | $4,850,000 | $2,865,000 | $2,547,000 |
| Cash Flow From Continuing Financing Activities | $-109,000 | $4,850,000 | $2,865,000 | $2,547,000 |
| Net Common Stock Issuance | $0 | $3,726,000 | $0 | - |
| Common Stock Issuance | $0 | $3,726,000 | $0 | - |
| Other | ||||
| Repayment Of Debt | $-293,000 | $0 | - | - |
| Issuance Of Debt | $184,000 | $1,124,000 | $2,865,000 | $2,547,000 |
| Interest Paid Supplemental Data | $0 | $0 | - | - |
| End Cash Position | $3,000 | $1,999,000 | $1,000 | $2,000 |
| Beginning Cash Position | $1,999,000 | $1,000 | $2,000 | $46,000 |
| Changes In Cash | $-1,996,000 | $1,998,000 | $-1,000 | $-44,000 |
| Net Issuance Payments Of Debt | $-109,000 | $1,124,000 | $2,865,000 | $2,547,000 |
| Net Short Term Debt Issuance | $-109,000 | $1,124,000 | $2,865,000 | $2,547,000 |
| Short Term Debt Payments | $-293,000 | $0 | - | - |
| Short Term Debt Issuance | $184,000 | $1,124,000 | $2,865,000 | $2,547,000 |
| Change In Working Capital | $600,000 | $-608,000 | $436,000 | $421,000 |
| Change In Payables And Accrued Expense | $468,000 | $-471,000 | $460,000 | $481,000 |
| Change In Accrued Expense | $-2,000 | $-35,000 | $167,000 | $57,000 |
| Change In Payable | $470,000 | $-436,000 | $293,000 | $424,000 |
| Change In Account Payable | $470,000 | $-436,000 | $293,000 | $424,000 |
| Change In Prepaid Assets | $126,000 | $-265,000 | $104,000 | $-60,000 |
| Change In Inventory | $7,000 | $0 | - | - |
| Change In Receivables | $-1,000 | $128,000 | $-128,000 | $0 |
| Changes In Account Receivables | $-1,000 | $128,000 | - | - |
| Other Non Cash Items | $10,371,000 | $-4,003,000 | - | - |
| Stock Based Compensation | $13,000 | $19,000 | $0 | - |
| Asset Impairment Charge | $419,000 | $25,356,000 | $0 | $4,100,000 |
| Deferred Tax | $-2,580,000 | $33,000 | $0 | $-621,000 |
| Deferred Income Tax | $-2,580,000 | $33,000 | $0 | $-621,000 |
| Depreciation Amortization Depletion | $1,145,000 | $1,119,000 | $1,120,000 | $1,113,000 |
| Depreciation And Amortization | $1,145,000 | $1,119,000 | $1,120,000 | $1,113,000 |
| Gain Loss On Sale Of PPE | $12,000 | $0 | - | - |
| Net Income From Continuing Operations | $-11,870,000 | $-24,770,000 | $-4,407,000 | $-7,255,000 |
| Net PPE Purchase And Sale | - | $0 | $-18,000 | $-276,000 |
| Purchase Of PPE | - | $0 | $-18,000 | $-276,000 |
| Net Investment Purchase And Sale | - | - | $0 | $-65,000 |
| Purchase Of Investment | - | - | $0 | $-65,000 |
| Amortization Cash Flow | - | - | - | $1,113,000 |
| Amortization Of Intangibles | - | - | - | $1,113,000 |
Fetched: 2026-06-23